Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer

Cy, Lu; Tsai, H-L; Uen, Y-H; Hu, Hongping; Cw, Chen; Cheng, Tao; Lin, SR; Jy, Wang

doi:10.1038/bjc.2012.595

Cited by 73 publications

(61 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include mRNA markers, such as human telomerase reverse transcriptase (hTERT), CK19, CK20, carcinoembryonic antigen (CEA) and CD133. The presence of these markers confer a HR for relapse and overall survival of at least 2.0, although differing detection methods and definitions for positivity were used 21 24 31 32. CTC counts also correlate with lymph node status, at least in a study of stage II and III CRC patients, and may be prognostic in stage III disease 18…”

Section: Circulating Tumour Cellsmentioning

confidence: 99%

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

et al. 2014

View full text Add to dashboard Cite

Circulating tumour cells (CTCs) hold great potential as liquid biopsies to prognosticate disease and guide treatment in colorectal cancer. However, their emerging role in determining the molecular phenotype of tumour metastasis carries even more promising clinical use in the provision of comprehensive biomarker detection for targeted therapies and determination of drug resistance. The isolation of CTCs is technology dependent, and in the case of epithelial cell adhesion molecule-based platforms, the ability to detect cells that have undergone the epithelial to mesenchymal transition (EMT) is ineffective. CTCs displaying a mesenchymal phenotype are believed to have an increased metastatic potential. The rarity of CTCs provides another challenge in the enumeration of these cells. The future will likely involve the analysis of individual CTCs at any stage of the EMT in order to provide real-time phenotypic and molecular snapshots capable of tracking the dynamic evolution of tumour progression over time.

show abstract

Section: Circulating Tumour Cellsmentioning

confidence: 99%

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…(7) used expression of cytokeratin 19 (CK19), CK20 or carcinoembryonic antigen (CEA) to identify CTCs, markers that we and others have reported show a high background expression in blood samples from patients with inflammatory bowel disease and result in an unacceptably high rate of false positives (6,7,13,23). Despite these shortcomings, CTC levels enumerated using the CellSearch system showed promise as an early treatment response marker in metastatic breast cancer and could be useful in clinical trials alone or in addition to radiological assessment of response (24 (25). Interestingly, in a clinical trial of a 4-drug regimen in advanced CRC, patients with high CTC numbers (detected by CellSearch) survived longer than expected compared with historical controls, whereas patients with low CTCs gained no extra benefit.…”

Section: Enrichment and Detection Of Ctcsmentioning

confidence: 99%

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress

Hardingham

Grover

Winter

et al. 2015

Mol Med

124

104

View full text Add to dashboard Cite

Circulating tumor cells (CTC) may be defined as tumor-or metastasis-derived cells that are present in the bloodstream. The CTC pool in colorectal cancer (CRC) patients may include not only epithelial tumor cells, but also tumor cells undergoing epithelial-mesenchymal transition (EMT) and tumor stem cells. A significant number of patients diagnosed with early stage CRC subsequently relapse with recurrent or metastatic disease despite undergoing "curative" resection of their primary tumor. This suggests that an occult metastatic disease process was already underway, with viable tumor cells being shed from the primary tumor site, at least some of which have proliferative and metastatic potential and the ability to survive in the bloodstream. Such tumor cells are considered to be responsible for disease relapse in these patients. Their detection in peripheral blood at the time of diagnosis or after resection of the primary tumor may identify those early-stage patients who are at risk of developing recurrent or metastatic disease and who would benefit from adjuvant therapy. CTC may also be a useful adjunct to radiological assessment of tumor response to therapy. Over the last 20 years many approaches have been developed for the isolation and characterization of CTC. However, none of these methods can be considered the gold standard for detection of the entire pool of CTC. Recently our group has developed novel unbiased inertial microfluidics to enrich for CTC, followed by identification of CTC by imaging flow cytometry. Here, we provide a review of progress on CTC detection and clinical significance over the last 20 years.

show abstract

“…CTCs may predict CRC recurrence/progression [91] and help select high-risk stage II patients for adjuvant chemotherapy [92]. CTCs have also been used as an outcome marker after chemotherapy [93].…”

Section: Emerging Applications For Ctcs -Therapy Monitoringmentioning

confidence: 99%

Clinical Utility of Circulating Tumor Cells – A Clinician’s Current View

Aw¹

2017

Hematol Med Oncol

View full text Add to dashboard Cite

With the advent of technology that can reliably detect them, interest in circulating tumor cells have escalated with over 18,000 publications and its involvement in 911 trials. Its presence in the blood stream connotes more aggressive and serious disease. This has led to a revision in the American Joint Commission on Cancer TNM classification for breast cancer. Presence of circulating tumor cells upcodes presumed non-metastatic breast cancer (M0) to an intermediate stage M0(i+). This review will describe the methods to capture and detect circulating tumor cells with a focus on the most analytically valid system -CellSearch. The studies underpinning the established uses of CTC enumeration in prognosis of metastatic cancers (breast, prostate and colon) will be highlighted as well as the imminent deployment in early breast cancer. Emerging applications in monitoring cancer treatment and promising indications in other cancers will also be examined.

show abstract

Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer

Cited by 73 publications

References 29 publications

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer—20 Years of Progress

Clinical Utility of Circulating Tumor Cells – A Clinician’s Current View

Contact Info

Product

Resources

About